Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies

S. Coco, G. P. Tonini, S. Stigliani, Paola Scaruffi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Neuroblastoma is an extracranial solid tumor which occurs in infants and young children and accounts for 8% of pediatric cancers. It origins from neural crest cells of the sympathetic nervous system. Disease-free survival ranges from 95% for localized tumors to 30% for metastatic disease in children over 1 year of age and patients' outcome depends on dissemination and tissue histology. Despite the most recent therapies, the overall survival for high risk patients is still low and the outcome is invariably fatal. Improvement of neuroblastoma treatment is one of the highest priorities in pediatric oncology and a major challenge to clinicians and researchers. Understanding the biology and genetics of pediatric malignancies will be the key to identify molecular targets for innovative treatments as well as to individual management of disease. The success of human genome project and recent advances in technology have provided new tools to investigate cancer cells and to discover new tumor-associated genes. High-throughput efforts include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays and expression microarrays. Here we present an overview on the most recent advances in wide-genome analysis of neuroblastoma. We also focus on the potential clinical application of genome and transcriptome information to the diagnosis, prognosis and neuroblastoma therapy.

Original languageEnglish
Pages (from-to)448-455
Number of pages8
JournalCurrent Pharmaceutical Design
Volume15
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Investigational Therapies
Gene Expression Profiling
Neuroblastoma
Genome
Neoplasms
Pediatrics
Human Genome Project
Comparative Genomic Hybridization
Neural Crest
Sympathetic Nervous System
Therapeutics
Disease Management
Transcriptome
Disease-Free Survival
Single Nucleotide Polymorphism
Histology
Research Personnel
Technology
Survival
Genes

Keywords

  • Array-CGH
  • Gene expression profiling
  • Meta-analysis
  • Methylation
  • Neuroblastoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies. / Coco, S.; Tonini, G. P.; Stigliani, S.; Scaruffi, Paola.

In: Current Pharmaceutical Design, Vol. 15, No. 4, 2009, p. 448-455.

Research output: Contribution to journalArticle

Coco, S. ; Tonini, G. P. ; Stigliani, S. ; Scaruffi, Paola. / Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies. In: Current Pharmaceutical Design. 2009 ; Vol. 15, No. 4. pp. 448-455.
@article{e49af82b1aea4412bd1222cf91e34047,
title = "Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies",
abstract = "Neuroblastoma is an extracranial solid tumor which occurs in infants and young children and accounts for 8{\%} of pediatric cancers. It origins from neural crest cells of the sympathetic nervous system. Disease-free survival ranges from 95{\%} for localized tumors to 30{\%} for metastatic disease in children over 1 year of age and patients' outcome depends on dissemination and tissue histology. Despite the most recent therapies, the overall survival for high risk patients is still low and the outcome is invariably fatal. Improvement of neuroblastoma treatment is one of the highest priorities in pediatric oncology and a major challenge to clinicians and researchers. Understanding the biology and genetics of pediatric malignancies will be the key to identify molecular targets for innovative treatments as well as to individual management of disease. The success of human genome project and recent advances in technology have provided new tools to investigate cancer cells and to discover new tumor-associated genes. High-throughput efforts include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays and expression microarrays. Here we present an overview on the most recent advances in wide-genome analysis of neuroblastoma. We also focus on the potential clinical application of genome and transcriptome information to the diagnosis, prognosis and neuroblastoma therapy.",
keywords = "Array-CGH, Gene expression profiling, Meta-analysis, Methylation, Neuroblastoma",
author = "S. Coco and Tonini, {G. P.} and S. Stigliani and Paola Scaruffi",
year = "2009",
doi = "10.2174/138161209787315792",
language = "English",
volume = "15",
pages = "448--455",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies

AU - Coco, S.

AU - Tonini, G. P.

AU - Stigliani, S.

AU - Scaruffi, Paola

PY - 2009

Y1 - 2009

N2 - Neuroblastoma is an extracranial solid tumor which occurs in infants and young children and accounts for 8% of pediatric cancers. It origins from neural crest cells of the sympathetic nervous system. Disease-free survival ranges from 95% for localized tumors to 30% for metastatic disease in children over 1 year of age and patients' outcome depends on dissemination and tissue histology. Despite the most recent therapies, the overall survival for high risk patients is still low and the outcome is invariably fatal. Improvement of neuroblastoma treatment is one of the highest priorities in pediatric oncology and a major challenge to clinicians and researchers. Understanding the biology and genetics of pediatric malignancies will be the key to identify molecular targets for innovative treatments as well as to individual management of disease. The success of human genome project and recent advances in technology have provided new tools to investigate cancer cells and to discover new tumor-associated genes. High-throughput efforts include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays and expression microarrays. Here we present an overview on the most recent advances in wide-genome analysis of neuroblastoma. We also focus on the potential clinical application of genome and transcriptome information to the diagnosis, prognosis and neuroblastoma therapy.

AB - Neuroblastoma is an extracranial solid tumor which occurs in infants and young children and accounts for 8% of pediatric cancers. It origins from neural crest cells of the sympathetic nervous system. Disease-free survival ranges from 95% for localized tumors to 30% for metastatic disease in children over 1 year of age and patients' outcome depends on dissemination and tissue histology. Despite the most recent therapies, the overall survival for high risk patients is still low and the outcome is invariably fatal. Improvement of neuroblastoma treatment is one of the highest priorities in pediatric oncology and a major challenge to clinicians and researchers. Understanding the biology and genetics of pediatric malignancies will be the key to identify molecular targets for innovative treatments as well as to individual management of disease. The success of human genome project and recent advances in technology have provided new tools to investigate cancer cells and to discover new tumor-associated genes. High-throughput efforts include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays and expression microarrays. Here we present an overview on the most recent advances in wide-genome analysis of neuroblastoma. We also focus on the potential clinical application of genome and transcriptome information to the diagnosis, prognosis and neuroblastoma therapy.

KW - Array-CGH

KW - Gene expression profiling

KW - Meta-analysis

KW - Methylation

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=64249151249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249151249&partnerID=8YFLogxK

U2 - 10.2174/138161209787315792

DO - 10.2174/138161209787315792

M3 - Article

C2 - 19199972

AN - SCOPUS:64249151249

VL - 15

SP - 448

EP - 455

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 4

ER -